Compare Liquidia Corp. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 3,479 Million (Small Cap)
NA (Loss Making)
NA
0.00%
1.61
-552.55%
157.74
Revenue and Profits:
Net Sales:
54 Million
(Quarterly Results - Sep 2025)
Net Profit:
-4 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
59.19%
0%
59.19%
6 Months
128.08%
0%
128.08%
1 Year
193.27%
0%
193.27%
2 Years
227.17%
0%
227.17%
3 Years
523.14%
0%
523.14%
4 Years
610.88%
0%
610.88%
5 Years
1242.3%
0%
1242.3%
Liquidia Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
82.64%
EBIT Growth (5y)
-186.52%
EBIT to Interest (avg)
-24.13
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.33
Sales to Capital Employed (avg)
0.22
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
75.78%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
31.19
EV to EBIT
-11.61
EV to EBITDA
-11.80
EV to Capital Employed
-90.05
EV to Sales
104.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-271.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 35 Schemes (14.09%)
Foreign Institutions
Held by 58 Foreign Institutions (4.35%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
54.30
8.80
517.05%
Operating Profit (PBDIT) excl Other Income
2.20
-37.20
105.91%
Interest
6.90
5.70
21.05%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.50
-41.60
91.59%
Operating Profit Margin (Excl OI)
32.50%
-4,244.10%
427.66%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 517.05% vs 183.87% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 91.59% vs -8.33% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
14.00
17.50
-20.00%
Operating Profit (PBDIT) excl Other Income
-119.10
-71.20
-67.28%
Interest
12.50
6.30
98.41%
Exceptional Items
-4.30
-2.30
-86.96%
Consolidate Net Profit
-130.40
-78.50
-66.11%
Operating Profit Margin (Excl OI)
-8,666.30%
-4,196.20%
-447.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -20.00% vs 10.06% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -66.11% vs -91.46% in Dec 2023
About Liquidia Corp. 
Liquidia Corp.
Pharmaceuticals & Biotechnology
Liquidia Corp operates through it's subsidiaries, Liquidia Technologies, Inc. and RareGen, LLC (RareGen). The Company, through Liquidia Technologies, Inc., is a late-stage clinical biopharmaceutical company focused on the development and commercialization of products using it's PRINT technology. It is focused on developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. RareGen provides commercialization for rare disease pharmaceutical products, such as generic Remodulin (treprostinil) for pulmonary arterial hypertension. Treprostinil can be administered as a continuous infusion through the use of an infusion pump or continuous intravenous infusion through the use of a central venous catheter.






